Iambic Therapeutics, the AI-driven drug developer that began trading on Nasdaq on Oct. 15 after a $150 million IPO, has stitched together roughly...
ByThe RegistryOctober 21, 2026 
Signup for news and special announcements!
You have successfully joined our subscriber list.
Error: Contact form not found.